Intel stock spikes after report of possible US government stake
Investing.com - Piper Sandler has reiterated an Overweight rating and $37.00 price target on NewAmsterdam Pharma Co NV (NASDAQ:NAMS), maintaining its positive outlook on the company’s lead drug candidate obicetrapib. According to InvestingPro data, analysts maintain a strong buy consensus with price targets ranging from $27 to $52.
NewAmsterdam Pharma stock has traded up approximately 20% over the past five days, according to Piper Sandler. InvestingPro data confirms this strong momentum, showing a 16.85% return over the past week and an impressive 45.54% gain over the past year. The firm hosted the company for two days of investor meetings in Boston, which reportedly generated strong interest despite a busy earnings week.
Piper Sandler views NAMS as one of its favorite stocks for 2025/2026, citing obicetrapib’s comprehensive benefits across multiple cardiovascular markers including LDL-C, Lp(a), LDL-P, ApoB, and others. The firm highlighted the drug’s clean safety profile and convenient once-daily oral dosing format.
The research note emphasized the large market opportunity for obicetrapib, pointing to approximately 40 million diagnosed hypercholesterolemia patients in the US who have not reached their LDL-C goals despite treatment.
Piper Sandler expects continued momentum for the stock ahead of Phase 3 PREVAIL cardiovascular outcomes trial results anticipated in the second half of 2026, which the firm believes is de-risked for a greater than 20% major adverse cardiovascular events benefit. Get deeper insights into NAMS’s financial health, growth prospects, and 13 additional exclusive ProTips with a subscription to InvestingPro.
In other recent news, NewAmsterdam Pharma announced promising results from its BROADWAY clinical trial, where its experimental drug obicetrapib significantly reduced plasma p-tau217, a key Alzheimer’s disease biomarker. This development is part of the company’s broader efforts to educate investors on the drug’s effects across various conditions, including atherosclerotic cardiovascular disease and diabetes. In anticipation of upcoming data from the PREVAIL trial, TD Cowen has reiterated a Buy rating on NewAmsterdam Pharma. Meanwhile, Citi initiated coverage with a Buy rating, highlighting obicetrapib’s market potential as a cholesterol-lowering drug. Goldman Sachs, however, initiated coverage with a Neutral rating, citing the extended timeline for the Phase 3 PREVAIL trial results expected in late 2026. Additionally, NewAmsterdam Pharma updated its employment agreement with Dr. John Kastelein, the chief scientific officer, outlining specific terms if his employment is terminated without cause. These developments reflect the company’s strategic focus on advancing its drug pipeline and managing executive roles.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.